Objectives: Two new versions of the sweat test have recently been developed with claimed advantages of being sensitive enough to quantify residual CFTR function and to measure efficacy of basic therapies. Methods: Rates of water evaporation (kg water/hr/m2 ) and of volume of sweat per gland (nL/min) were measured in a healthy female, 61 yrs, following the reported test protocols. Results: Cholinergic stimulation gave normal results (maximal evaporimetric response 5 min after intradermal injection of carbachol: 95.1 kg water/hr/m2 and gland secretion rate obtained 10 min after methacholine injection: 1.8 nL/min). However, the β-adrenergic (isoprenaline plus aminophylline) stimulation, induced in the presence of atropine to block cholinergic stimulation, was abolished (β-adrenergic/cholinergic ratio: 0 and 5.8% of the normal values for evaporimetry and bubble test, respectively), eliciting a diagnosis of CF. The results were confirmed by repeating each test at least twice. Sweat chlo...
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Le dépôt institutionnel DIAL est destiné au dépôt et à la diffusion de documents scientifiques émanents des membres de l'UCLouvain. Toute utilisation de ce document à des fin lucratives ou commerciales est strictement interdite. L'utilisateur s'engage à respecter les droits d'auteur lié à ce document, principalement le droit à l'intégrité de l'oeuvre et le droit à la paternité. La politique complète de copyright est disponible sur la page Copyright policy DIAL is an institutional repository for the deposit and dissemination of scientific documents from UCLouvain members. Usage of this document for profit or commercial purposes is stricly prohibited. User agrees to respect copyright about this document, mainly text integrity and source mention. Full content of copyright policy is available at Copyright policy Martinican origin. In vivo functional tests and in vitro assays were performed. Ion transport measurements in nasal and rectal mucosa displayed ENaC hyperactivity and CFTR dysfunction. Biochemical analysis showed that F1099L-CFTR was not fully mature, this decreased processing was further confirmed by inspection of its subcellular localization on confocal microscopy, showing that F1099L-CFTR was weakly expressed at the plasma membrane. Treatment with VX-809 alone or in combination with VX-770 completely corrected the processing defect. Finally, our results were further completed by the 3D structure model, which predicted the effect of this mutation on the CFTR protein and the mechanism of correction by VX-809. We propose extensive genotyping in severe CRS to discover rare mutations which could be treated by CFTR correctors to postpone pulmonary infection.
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Nasal potential difference in young children is feasible Objectives: The diagnosis of cystic fibrosis is based on characteristic clinical symptoms and either a positive sweat test or identification of related mutations on each of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene alleles. A significant number of patients have no definite diagnosis, having possibly related symptoms, borderline sweat test and no identifiable known mutation on the CFTR gene. Nasal Potential Difference (NPD) is an established method of diagnosis in these patients. Until now standard values for very young patients have not been developed and validated. The aim of this study was to evaluate the feasability of NPD in young children. Methods: The standard protocol for NPD was adapted for young children.
In the standard protocol infusions of amiloride, chloride-free and isoproterenol are for 3 minutes. In the current protocol this was reduced to 2 minutes so the entire test is completed in 10 minutes. Results: 35 children aged 2 months to 3 years of age were enrolled in the study. Diagnoses included Failure to thrive (15), chronic diarrhea (6), respiratory problems (10), meconium plug (2). Mean sweat test was 53mmol/L. The NPD was abnormal (e Δchlor/ΔAmil > 0.7 was defined as an abnormal NPD while e Δchlor/ΔAmil < 0.7 was defined as a normal NPD) in 6 patients and these children were referred for follow up in CF Centers. The procedure was tolerated in all children. Conclusion: NPD is feasible in young children and may be useful in the diagnosis of CF in questionable cases.
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Topical eye treatment with β-blocker abolishes sweat secretion triggered by intradermal isoprenaline plus aminophylline: a clinical observation Objectives: Two new versions of the sweat test have recently been developed with claimed advantages of being sensitive enough to quantify residual CFTR function and to measure efficacy of basic therapies. Methods: Rates of water evaporation (kg water/hr/m 2 ) and of volume of sweat per gland (nL/min) were measured in a healthy female, 61 yrs, following the reported test protocols. Results: Cholinergic stimulation gave normal results (maximal evaporimetric response 5 min after intradermal injection of carbachol: 95.1 kg water/hr/m 2 and gland secretion rate obtained 10 min after methacholine injection: 1.8 nL/min). However, the β-adrenergic (isoprenaline plus aminophylline) stimulation, induced in the presence of atropine to block cholinergic stimulation, was abolished (β-adrenergic/cholinergic ratio: 0 and 5.8% of the normal values for evaporimetry and bubble test, respectively), eliciting a diagnosis of CF. The results were confirmed by repeating each test at least twice. Sweat chloride after pilocarpine iontophoresis using a coulometric method was 24 mmol/L. PCR-based screening showed no CFTR mutation. History of current medications possibly interfering with the pharmacological agents used during the tests revealed long-term (>12 yrs) treatment of a well-controlled primary angle closure glaucoma consisting on a daily topical use of β-blocker carteol 2% (1 drop/left eye). No apparent symptom of β-blocker intoxication is present (heart rate: 66 beats/min, regular sinus rhythm, no symptom of asthma). Conclusion: Much attention should be paid to the use of medications that may interfere with the pharmacological steps of the β-secretion tests. The clinical observation confirms the proof-of-concept that the second phase of both tests directly evaluates β-adrenergic sweat production that is very sensitive to β-blocker treatment, even at topical eye use, leading to false positive test results.
